Snipping a gene to reduce bad cholesterol for life looks possible

Live updates

1. 16d ago

   CRISPR Gene-Editing Therapy Lowers Cholesterol and Triglycerides

   A first-in-human trial of CTX310, a CRISPR gene-editing therapy from CRISPR Therapeutics, demonstrated a safe and continuous reduction of LDL cholesterol and triglycerides over one year. Data presented at the ESC Congress 2026 show the treatment achieves deep and durable editing of the ANGPTL3 gene. This single-time administration suggests the possibility of reducing bad cholesterol for life. Following these Phase 1a results, CRISPR Therapeutics intends to pursue the highest dose of the lipid-lowering therapy in future development.

   Why it matters

   High cholesterol and triglycerides are primary drivers of cardiovascular disease. Current treatments typically require daily medication or frequent injections. A one-time genetic modification could remove the need for lifelong pharmaceutical adherence.

   What is confirmed

   • The first-in-human trial of CRISPR gene-editing therapy safely and continuously lowered cholesterol and triglycerides after one year.
   • CTX310 demonstrates deep and durable ANGPTL3 editing and LDL lowering.
   • The treatment is administered as a single-time dose.

   Still unconfirmed

   • Snipping a gene to reduce bad cholesterol for life looks possible.
   • CRISPR Therapeutics will pursue the highest dose of its lipid lowering gene editing therapy.

   What to watch next

   • Results from higher-dose cohorts of the CTX310 trial
   • Long-term safety data beyond the one-year mark
   • Peer-reviewed publication of the Phase 1a data
   Sources used for this update (6)

   1. The New York Times — An Experimental Single-Time Treatment Slashed Cholesterol for a Year
   2. Cleveland Clinic Newsroom — Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year
   3. CNN — Snipping a gene to reduce bad cholesterol for life looks possible
   4. Time Magazine — A One-Time Treatment for High Cholesterol Shows Promising Results
   5. Endpoints News — #ESC26: CRISPR Therapeutics to pursue highest dose of its lipid lowering gene editing therapy
   6. Yahoo Finance — CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
   confidence 90%